Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott v. Mead Johnson

Executive Summary

Indianapolis federal court judge denies Abbott request for preliminary injunction against Bristol-Myers Squibb subsidiary for its marketing of Ricelyte oral electrolyte maintenance solution. Abbott, which sells market-leading Pedialyte, filed suit in February and sought an injunction to prohibit Bristol/Mead Johnson from making superiority claims for its product and from marketing a product with a "confusingly similar" name and packaging to Pedialyte. The judge "found certain advertising claims" by Mead Johnson "to be false and misleading," Abbott maintained. The judge, however, ruled "that monetary damages, if awarded following a trial, would be sufficient to compensate Abbott," and that "an injunction would harm the public interest by eliminating competition." A "full trial will follow at which all of the evidence will be submitted and at which we expect to prevail," Mead Johnson maintained.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel